An international clinical trial found that new drug aficamten boosts exercise capacity and quality of life for obstructive hypertrophic cardiomyopathy patients.
New Treatment in Pipeline for Patients with Hypertrophic Cardiomyopathy dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.
Ninerafaxstat improves symptoms, quality of life in nonobstructive HCM healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with evidence of improvements in symptoms and exercise capacity among people with nonobstructive hypertrophic cardiomyopathy (HCM), according to results of a 12-week phase 2 trial presented at the American College of Cardiology's Annual Scientific Session.